

To: Lauren Zeise (Lauren.Zeise@oehha.ca.gov)[Lauren.Zeise@oehha.ca.gov]; LE CURIEUX Frank[Frank.LECURIEUX@echa.europa.eu]; Ross, Matthew[MRoss@cvm.msstate.edu]; Martin, Matt[Martin.Matt@epa.gov]
From: Rusyn, Ivan
Sent: Tue 2/10/2015 4:45:30 PM
Subject: FW: IARC mono vol 112 section 4
report (23).docx

Cancer in humans

exp

– Identify established and likely mechanistic events

Are there co
the overa
Has each m
suppressi
of tumour
Are there alt
(Uneven sup
uneven re

– Determine whether each mechanism could operate in humans

Could differ
humans and

From: Kathryn Guyton [mailto:GuytonK@iarc.fr]
Sent: Tuesday, February 10, 2015 6:26 AM
To: Rusyn, Ivan
Subject: IARC mono vol 112 section 4

Bonjour Ivan!

In anticipation of the call today, kindly see the below the status of vol 112 Section 4 contributions. Matt Ross has completed everything, including a draft of 4.6 Mechanistic considerations for parathion! Others are in various states of completion. All submitted drafts have been sent for peer review.

Questions for you below, and let me know of anything else you'd like to discuss.

Thank you Ivan!!

Kate

Questions:

— Unless you would disagree, I wouldn't adjust assignments... nonetheless all drafts should be submitted/reviewed/revise within 2 weeks (24 Feb).

— what due date (suggest 24 Feb) and format do you want to use for Section 4.6? If you prefer a tabular summary of key evidence, this could be done in the Table Builder or using the attached Word file. Otherwise, we can propose one of the vol 110s as a model?

Le Curieux Frank (4 /
6)

DZN 4.2.1 Genetic and related effects
(*****DIAZINON*****)
(2015-01-13)
GLYP 4.2.1 Genetic and related effects
(*****GLYPHOSATE***)
(2015-01-13)
MAL 4.2.1 Genetic and related effects
(*****MALATHION*****)
(2015-01-13)
PAR 4.2.1 Genetic and related effects
(*****PARATHION*****)
(2015-01-13)
TCVP 4.6 Mechanistic considerations
(*****TETRACHLOR*****)
(2015-02-13)
TCVP 4.2.1 Genetic and related effects
(*****TETRACHLOR*****)
(2015-01-13)

Ross Matthew K. (6 /
6)

DZN 4.1. Toxicokinetic data
(*****DIAZINON*****)
(2015-01-13)
GLYP 4.1. Toxicokinetic data
(*****GLYPHOSATE***)
(2015-01-13)
MAL 4.1. Toxicokinetic data
(*****MALATHION*****)
(2015-01-13)
PAR 4.1. Toxicokinetic data
(*****PARATHION*****)
(2015-01-13)
PAR 4.6 Mechanistic considerations
(*****PARATHION*****)
(2015-02-13)
TCVP 4.1. Toxicokinetic data
(*****TETRACHLOR*****)
(2015-01-13)

Zeise Lauren (12 /
15)

DZN 4.2.4 Altered cell proliferation or death

(*****DIAZINON*****)
(2015-01-13)
DZN 4.2.2 Receptor-
mediated effects
(*****DIAZINON*****)
(2015-01-13)
DZN 4.2.5 Other
mechanisms
(*****DIAZINON*****)
(2015-01-13)
DZN 4.6 Mechanistic
considerations
(*****DIAZINON*****)
(2015-02-13)
GLYP 4.2.2 Receptor-
mediated effects
(*****GLYPHOSATE**
(2015-01-13)
GLYP 4.2.4 Altered cell
proliferation or death
(*****GLYPHOSATE**
(2015-01-13)
GLYP 4.2.5 Other
mechanisms
(*****GLYPHOSATE**
(2015-01-13)
MAL 4.2.2 Receptor-
mediated effects
(*****MALATHION*****)
(2015-01-13)
MAL 4.2.5 Other
mechanisms
(*****MALATHION*****)
(2015-01-13)
MAL 4.2.4 Altered cell
proliferation or death
(*****MALATHION*****)
(2015-01-13)
PAR 4.2.2 Receptor-
mediated effects
(*****PARATHION*****)
(2015-01-13)
PAR 4.2.4 Altered cell
proliferation or death
(*****PARATHION*****)
(2015-01-13)
PAR 4.2.5 Other
mechanisms
(*****PARATHION*****)
(2015-01-13)
TCVP 4.2.2 Receptor-
mediated effects
(*****TETRACHLOR
(2015-01-13)
TCVP 4.2.3 Other
mechanisms

(*****TETRACHLOR

(2015-01-13)

Martin Matthew T. (1 /
9)

DZN 4.3. Data relevant
to comparisons across
agents and endpoints

(*****DIAZINON*****

(2015-01-13)

DZN 4.5 Other adverse
effects

(*****DIAZINON*****

(2014-11-18)

GLYP 4.3. Data
relevant to comparisons
across agents and
endpoints

(*****GLYPHOSATE*

(2015-01-13)

GLYP 4.5. Other
adverse effects

(*****GLYPHOSATE*

(2015-01-13)

MAL 4.3. Data relevant
to comparisons across
agents and endpoints

(*****MALATHION*****

(2015-01-13)

MAL 4.5. Other adverse
effects

(*****MALATHION*****

(2015-01-13)

MAL 4.6 Mechanistic
considerations

(*****MALATHION*****

(2015-02-13)

PAR 4.5. Other adverse
effects

(*****PARATHION*****

(2015-01-13)

TCVP 4.5. Other
adverse effects

(*****TETRACHLOF

(2015-01-13)

Rusyn Ivan (9 /
12)

DZN 4.2.3 Oxidative
stress, inflammation
and
immunosuppression

(*****DIAZINON*****

(2015-01-13)

DZN 4.4. Cancer

susceptibility data
(*****DIAZINON*****
(2015-01-13)
GLYP 4.4. Cancer
susceptibility data
(*****GLYPHOSATE*
(2015-01-13)
GLYP 4.6 Mechanistic
considerations
(*****GLYPHOSATE*
(2015-02-13)
GLYP 4.2.3 Oxidative
stress, inflammation
and
immunosuppression
(*****GLYPHOSATE*
(2015-01-13)
MAL 4.2.3 Oxidative
stress, inflammation
and
immunosuppression
(*****MALATHION*****
(2015-01-13)
MAL 4.4. Cancer
susceptibility data
(*****MALATHION*****
(2015-01-13)
PAR 4.3. Data relevant
to comparisons across
agents and endpoints
(*****PARATHION*****
(2015-01-13)
PAR 4.4. Cancer
susceptibility data
(*****PARATHION*****
(2015-01-13)
PAR 4.2.3 Oxidative
stress, inflammation
and
immunosuppression
(*****PARATHION*****
(2015-01-13)
TCVP 4.3. Data
relevant to comparisons
across agents and
endpoints
(*****TETRACHLOF
(2015-01-13)
TCVP 4.4. Cancer
susceptibility data
(*****TETRACHLOF
(2015-01-13)